From 20 October till 24 October 2023: HIGHLIGHTS FROM ESMO

Your direct line with Madrid

The European Society of Medical Oncology (ESMO) 2023 brings together leading experts in the different fields of cancer from around the world. And this year they gather together in Madrid, Spain. The MediMix team is also onsite, and will – together with your Belgian colleagues – keep you posted about the hottest topics as they happen. And, we dive into posters and hot topics with the experts as they are being presented.

Stay tuned, and get ready for an exciting and informative journey!

With the educational support of:

Daily highlights in GI

Daily highlight in gastrointestinal tumours

Two investigations were presented concerning RAS-wildtype unresectable metastatic colon cancer, employing FOLFOXIRI treatment paired with the antibody therapy cetuximab.
The first, TRICE, was a randomized clinical trial comparing the chemotherapy

See video »

Daily highlight in NETs and endocrine tumours

The LIBRETTO-531 study was specifically structured to explore the optimal primary treatment approach for individuals diagnosed with advanced medullary thyroid carcinoma (MTC). The study involved a meticulous comparison between selpercatinib

See video »

Daily highlight in gastrointestinal cancer

The KEYNOTE-585 and MATTERHORN studies delve into the role of adjuvant and neoadjuvant treatment involving checkpoint inhibitors in gastric cancer. Both trials randomise patients into groups undergoing chemotherapy before and

See video »

In-depth stories about GI

The CABINET study

As anticipated and subsequently confirmed, the CABINET study confirms that Vascular Endothelial Growth Factor (VEGF) inhibitors demonstrate efficacy not only in pancreatic Neuroendocrine Tumors (NETs) but also in extrapancreatic sites.

See video »

The CABATEN/GETNE-T1914 study

The CABATEN/GETNE-T1914 study constituted a comprehensive investigation across multiple cohorts to assess the synergistic impact of cabozantinib, a multi-kinase inhibitor, and atezolizumab, a PD-L1 inhibitor. The outcomes yielded results of

See video »

GI poster selection

The AVETUXIRI phase II study

Prof Marc van den Eynde, digestive oncologist at Cliniques Universitaires Saint-Luc in Brussels, presented the results of the AVETUXIRI phase II study with the combination of avelumab, cetuximab and irinotecan

See video »

With the educational support of:

Z1. Researchpark 30, 1731 Zellik, Belgium
Website created by MediMix © 2023 - Privacy Policy